|
Originally published In Press as doi:10.1074/jbc.M205085200 on August 22, 2002
J. Biol. Chem., Vol. 277, Issue 44, 42188-42196, November 1, 2002
Inhibition of Glucocorticoid-induced Apoptosis in 697 Pre-B
Lymphocytes by the Mineralocorticoid Receptor N-terminal Domain*
Sonia L.
Planey ,
Assia
Derfoul§,
Andrzej
Steplewski,
Noreen M.
Robertson, and
Gerald
Litwack¶
From the Department of Biochemistry and Molecular Pharmacology,
Jefferson Medical College, Thomas Jefferson University,
Philadelphia, Pennsylvania 19107
Received for publication, May 23, 2002, and in revised form, August 20, 2002
 |
ABSTRACT |
The glucocorticoid and mineralocorticoid
receptors (GR and MR) share considerable structural and functional
homology and bind as homodimers to hormone-response elements. We have
shown previously that MR and GR can form heterodimers that inhibit
transcription from a glucocorticoid (GC)-responsive gene and that this
inhibition was mediated by the N-terminal domain (NTD) of MR. In this
report, we examined the effect of NTD-MR on GC-induced apoptosis in the GC-sensitive pre-B lymphoma cell line, 697. In GC-treated 697 cells, we
demonstrated that stable expression of NTD-MR blocks apoptosis and
inhibits proteolytic processing of pro-caspases-3, -8, and -9 and
poly(ADP-ribose) polymerase. Importantly, gel shift and
immunoprecipitation analyses revealed a direct association between the
GR and amino acids 203-603 of NTD-MR. We observed down-regulation of
c-Myc and of the anti-apoptotic proteins Bcl-2 and Bfl-1 as well as
high levels of the pro-apoptotic proteins Bax and Bid. Conversely,
cells stably expressing NTD-MR exhibited increased expression of Bcl-2
and Bfl-1 and diminished levels of Bid and Bax. These data provide a
potential mechanism for the observed inhibition of cytochrome
c and Smac release from the mitochondria of NTD-MR cells
and resultant resistance to GC-induced apoptosis. Thus, NTD-MR may
mediate GC effects through heterodimerization with GR and ensuing
inhibition of GC-regulated gene transcription.
 |
INTRODUCTION |
The glucocorticoid and the mineralocorticoid receptors
(GR1 and MR) are closely
related members of the steroid receptor superfamily, with high sequence
homology within the DNA binding and ligand binding domains (1). These
receptors function as ligand-activated transcription factors that
control various aspects of metabolic homeostasis, embryonic
development, and physiological stress by binding to specific
hormone-response elements in the regulatory regions of target genes
(2). In vitro, both the GR and the MR bind to and are
activated by the physiological glucocorticoid (GC), cortisol. Although
both receptors, when activated, can bind and transactivate
glucocorticoid-response elements (GREs) in the promoters of target
genes, each has distinct transcriptional activities (3, 4). For
instance, the GR, but not the MR, self-synergizes at multimerized
hormone-response elements (5, 6), and only the GR can inhibit induction
of AP-1-dependent genes by Fos-Jun heterodimers (7). In
addition, the ability to mediate apoptosis in susceptible cells is
exclusive to the GR (8).
Induction of apoptosis by GCs occurs in numerous cell types including
immature lymphocytes and various malignancies of lymphoid origin (9,
10). Evidence that the GR is essential for this process has been
provided by studies using GR antagonists, such as RU486, that
completely block GC-induced cell death and by experiments involving GR
knockout mice (11-13). The effects of mutations in the GR on its
ability to cause apoptosis vary among cell lines. In human CEM and
Jurkat lymphoid cells, the DNA binding domain and the ligand binding
domain of the GR are essential for GC-induced cell death. Specifically,
mutations that deleted either of the zinc fingers of the DNA binding
domain or substituted amino acids in critical sites within the
N-terminal zinc finger completely blocked the lethal response (14).
Ligand binding domain mutations also inhibited cell death demonstrating
a requirement for hormone binding (15). GR mutants lacking the
N-terminal transactivation domain did not prevent apoptosis in these
cell lines; however, in S49 mouse lymphoma cells, this region was
essential for steroid-induced lethality (16).
Differences in the transcriptional activities of the GR and the MR,
including the ability to mediate apoptosis, may be attributed to
structural variability within the N-terminal domain (NTD). This region
contains a transactivation function, AF-1, which is involved in the
transcriptional transactivation of genes, in receptor heterodimerization, and in binding to other transcription factors (17).
Moreover, in the absence of a ligand binding domain, this region is
constitutively active. The NTDs of GR and MR share only 15% sequence
homology and have been shown to have opposite transactivation properties (1). Specifically, chimeric receptor analyses demonstrated that this region of the MR is inhibitory for GR-mediated regulation of
the Na/K-ATPase 1 gene promoter when MR and GR are coexpressed (18).
In addition, several laboratories (5, 18-20) have shown that GR and MR
can form heterodimers capable of inhibiting transcription from a
GC-responsive gene.
Although the functional consequences of MR/GR heterodimerization are
not well understood, the possible physiological significance stems from
the observed co-localization of the receptors in various tissues and
cells including the brain, heart, vascular smooth muscle, and
leukocytes (21-24). For example, in the brain, the MR is involved in
the excitability of neurons, whereas the GR opposes these effects.
Moreover, in the dentate gyrus of the hippocampus, there is evidence
that MR activation can protect neurons against acute GR ligand-mediated
apoptosis (25). A recent study has also demonstrated that
heterodimerization of MR and GR mediates direct corticosteroid-induced
transrepression of the 5-HT1A receptor promoter (20). These studies
have prompted us to examine whether the MR can mediate or abrogate
apoptotic cell death in the GC-sensitive pre-B lymphoma cell line, 697.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Restriction enzymes and other reagents were
obtained from Promega (Madison, WI), Roche Molecular Biochemicals, or
New England Biolabs (Beverly, MA). Horseradish peroxidase-conjugated
antibodies, ECL reagents, and Hybond membranes were purchased from
Biosciences. Triamcinolone acetonide (TA), a synthetic GC analog, was
purchased from Sigma. All tissue culture media and supplements were
from Invitrogen. All other chemicals were purchased from Fisher.
Cell Lines and Culture Conditions--
The 697 cell line is a
cloned human pre-B leukemic cell line derived from childhood acute
lymphoblastic leukemia that carries the t(1;19) translocation (26, 27).
These cells were cultured with RPMI media supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, penicillin at
100 units/ml, and streptomycin at 100 µg/ml at 37 °C under 5%
CO2 in a humidified atmosphere. Exponentially growing cells
were used throughout all experiments at a concentration of 5 × 105-1 × 106 cells/ml. The cells were
treated with TA at a concentration of 1 µM. After steroid
treatment, cells were harvested by centrifugation at 1500 × g for 5 min and washed twice with phosphate-buffered saline
(PBS).
Generation of Stably Transfected Cell Lines--
The N-terminal
domain of MR (NTD-MR) or of GR (NTD-GR) was subcloned from the original
RshMR or RshGR plasmids (gifts from Dr. R. M. Evans), respectively, into the mammalian expression vector
pCMV/myc/nuc (Invitrogen) using the SalI/NotI
restriction sites. This vector contains a C-terminal c-Myc epitope tag
and three tandem nuclear localization signals located downstream of the
multiple cloning site. Consequently, the expression of the NTD-MR/c-Myc
and NTD-GR/c-Myc fusion proteins, which lack the domains required for
translocation, would be efficiently targeted to the nucleus. Following
sequence confirmation, these constructs were stably transfected into
the 697 cell line. Cells (6 × 106) were transfected
with the Effectene reagent (Qiagen, Valencia, CA) and either 1 µg of
the NTD-MR plasmid, the NTD-GR plasmid, or the empty vector and
selected by G418 resistance. G418-resistant cells were subcloned by
limiting dilution, and fusion protein expression was evaluated by
Western blot using a c-Myc monoclonal antibody (mAb) (Invitrogen).
The generation of NTD-MR derivatives 1-103, 1-203, 1-303, 1-403,
and 1-603 was carried out by PCR amplification of the pRshMR plasmid
using the forward primer, MRfor-ATG-SalI,
5'-CCCCGTCGACATGGAGACCAAAGGCTACCAC-3', and the reverse primers
MRrev103-NotI, 5'-GGGGGGGGCGGCCGCCTCAGCTACAGTTGCTGA-3', MRrev203-NotI, 5'-GGGGGGGGCGGCCGCCGAAGATGTCATGTTCAG-3',
MRrev303-NotI, 5'-GGGGGGGGCGGCCGCAATATTTGCAGGGCTAGA-3',
MRrev403-NotI, 5'-GGGGGGGGCGGCCGCATCTGGTTCTGGTTTTAT-3', and
MRrev603-NotI,
5'-GGGGGGGGCGGCCGCTTGGGCAAAGGTAAATAC-3'. These constructs were
subsequently cloned into the pCMV/myc/nuc vector using
SalI/NotI restriction sites and stably
transfected into 697 cells as described above.
Determination of Cell Number and Viability--
Cells (1 × 106 cells/ml) were seeded in 24-well plates and incubated
at 37 °C for 2 days in the presence or absence of 1 µM TA. Throughout the 48-h time course, cell viability was determined by
trypan blue exclusion using a hemocytometer. For TUNEL staining, cells
were treated with 1 µM TA for 0, 24, or 48 h and
spun onto slides using a cytospin centrifuge. The cells were fixed with 4.0% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4)
for 15 min at room temperature and subsequently washed three times with PBS for 5 min. Cells were permeabilized with 0.1% Triton X-100, 0.1%
sodium citrate, labeled with TUNEL reaction mixture (Roche Molecular
Biochemicals), and incubated in a humidified chamber for 60 min at
37 °C in the dark. After rinsing 3 times with PBS, the cells were
mounted in Vectashield with 4,6-diamidino-2-phenylindole counterstain
(Vector Laboratories, Burlingame, CA) and examined with a Zeiss
Axiovert 405M microscope using epifluorescence microscopy and
photographed using a Phase 3 Imaging System with Cool Spot RT digital
camera (Phase 3 Imaging Systems, Glen Mills, PA).
Gel Electrophoresis and Western Blotting--
Proteins were
electrophoresed in 8, 10, or 12% SDS-polyacrylamide gels and
transferred to nitrocellulose for Western blotting. Membranes were
blocked overnight with 10% nonfat milk, 1× PBS, 0.1% Tween 20 and
incubated with the -active caspase-3 rabbit polyclonal antibody
(pAb) (1:1000) (BD Biosciences), -Myc mouse mAb (1:5000)
(Invitrogen), -caspase-8 mouse mAb (0.5 µg/ml) (BD Biosciences), -caspase-9 rabbit pAb (1:1000) (BD Biosciences), or
the PARP mouse mAb (1:200) (BD Biosciences) in 1× PBS, 5% nonfat milk
for 1 h at room temperature, followed by a 1-h incubation with
horseradish peroxidase-labeled donkey anti-rabbit or sheep anti-mouse
antibodies (1:2500). Proteins were detected using ECL reagent.
Immunofluorescence--
NTD-MR (MR-H7) cells were harvested
1 h after treatment with 1 µM TA, spun onto slides,
and fixed with 70% methanol, 30% acetone for 10 min at 20 °C and
5 min at room temperature. Cells were blocked for 30 min with 5%
normal goat serum (NGS) in PBS and then incubated with avidin D
blocking solution (Vector Laboratories) for 15 min. Slides were washed
in PBS, 0.05% Tween 20, incubated with biotin blocking solution
(Vector Laboratories) for 15 min, washed again, and incubated overnight
at 4 °C with preimmune serum or GR pAb (5 µg/ml). Slides were
washed in PBS, 0.05% Tween and incubated for 2 h at room
temperature with biotinylated anti-rabbit IgG (5 µg/ml; Vector
Laboratories) diluted in 5% NGS/PBS. Slides were washed in PBS
0.05% Tween and incubated with Texas Red avidin (20 µg/ml;
Vector Laboratories) diluted in 5% NGS/PBS for 1.5 h at room
temperature. Slides were washed in PBS prior to air drying, mounted in
Vectashield (Vector Laboratories), and visualized as described
for TUNEL analysis.
Electrophoretic Mobility Shift Assay--
A double-stranded
oligonucleotide corresponding to a GRE from the human Na/K-ATPase 1
gene ( wt MRE) at position 662 to 628
GGGTTTGGCAATTGTCCTGCTCGAGGTGGTTCAGG was synthesized. 1 wt MRE was
filled using the Klenow fragment (Roche Molecular Biochemicals) and
labeled by incorporating [ -32P]CTP (PerkinElmer Life
Sciences) for use as a probe. Nuclear extracts of TA-treated 697 cells
with vector or NTD-MR (3-6 µg) were incubated on ice for 10 min in
10 mM Tris-HCl (pH 7.5), 80 mM KCl, 10%
glycerol, 1 mM dithiothreitol, 1 mM of
poly(dI-dC), in a total volume of 18 µl. c-Myc mAbs ( -Myc)
(Invitrogen or CN Biosciences, San Diego, CA) or MR pAbs ( MR
recognizing the N terminus and hMRsN recognizing a 10-amino acid
peptide within the N terminus) (28), as well as preimmune serum and a
GR pAb ( GR) were included in reaction mixtures where indicated. 0.1 ng of 5' 32P-end-labeled 1 wt MRE was added
to the reaction, and incubation was continued for 10 min at room
temperature. Reaction mixtures were applied to a 4% non-denaturing
polyacrylamide gel, and DNA-protein complexes were resolved by
electrophoresis (250 V) at 4 °C, with buffer recirculation in 1×
TAE (6.7 mM Tris-HCl (pH 7.5), 3.3 mM sodium
acetate, 1 mM EDTA). The gel was dried under vacuum and
autoradiographed at 80 °C.
Immunoprecipitations--
Following a 1-h treatment with 1 µM TA, 2.0 × 107 697 cells with either
vector, NTD-MR, or stably expressed NTD-MR derivatives 1-103, 1-203,
1-303, 1-403, and 1-603 were harvested by low speed centrifugation.
Cells were disrupted using ice-cold RIPA buffer (1× PBS, 1% Nonidet
P-40, 0.5% sodium deoxycholate, 0.1% SDS) containing fresh protease
inhibitors and homogenized with passage through a 21-gauge needle.
After incubation on ice, the samples were centrifuged at 10,000 × g, and the resulting cell lysates were precleared for 1 h at 4 °C with agitation using 2 µg of mouse IgG (Vector
Laboratories) and 20 µl of protein A/G-agarose conjugate (Santa Cruz
Biotechnology, Santa Cruz, CA). The beads were pelleted by
centrifugation for 5 min at 2500 rpm at 4 °C, and the supernatants were transferred to a fresh tube. c-Myc mAb (2 µg/ml) was added to 1 ml of each cell extract, and the mixtures were rocked for 1 h at
4 °C. Then 20 µl of protein A/G-agarose conjugate was added to
each sample for overnight incubation at 4 °C in a rotating device.
Precipitates were collected by centrifuging at 2500 rpm for 5 min at
4 °C, washed 4 times with RIPA buffer and once with PBS, and
resuspended in 40 µl of 1× SDS-electrophoresis buffer.
Isolation and Analysis of RNA--
After steroid treatment,
cells were harvested by centrifugation and then frozen immediately on
dry ice. Total cell RNA was isolated from frozen samples using the
RNeasy® kit from Qiagen. RNA concentrations were determined by
measuring the absorbance of each sample at 260 and 280 nm. Analysis of
RNA for repression of c-Myc expression was carried out using RT-PCR and
Northern blot analyses. RT-PCR was performed on 1 µg of each RNA
sample using the TITANIUMTM One-step RT-PCR Kit (BD
Biosciences) and c-Myc- or GAPDH-specific primer pairs (c-Myc forward,
5'-ATGCCCCTCAACGTTAGCTTCACCAACAGG-3', c-Myc reverse,
5'-TTACGCACAAGAGTTCCGTAGCTGTTCAAG-3'; GAPDH forward, 5'-CCACCCATGGCAAATTCCATGGCA-3', GAPDH reverse
5'-TCTAGACGGCAGGTCAGGTCCACC-3'). The amplification was performed
as follows: 50 °C/1 h, 94 °C/5 min, 30 cycles of
94 °C/30 s, 65 °C/30 s, 68 °C/1 min, and then 68 °C/2 min.
PCR products were separated by electrophoresis in a 1.0% agarose gel
and visualized by ethidium bromide staining. Band intensities were
quantitated using Kodak 1D Imaging Software (Eastman Kodak Co.), and
fold induction of mRNA expression was normalized to the level of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
For Northern blot analysis, RNA samples (15 µg each) containing 0.2 µg/ml ethidium bromide were fractionated in a 1.2%
formaldehyde-agarose gel. The gel was photographed, rinsed in 10× SSC,
and transferred by blotting to Hybond-N nylon membrane (Amersham
Biosciences) with 20× SSC. Accuracy of RNA loading and transfer was
confirmed by fluorescence under ultraviolet light after staining with
ethidium bromide. The RNA was UV cross-linked to the membrane,
prehybridized, and hybridized at 42 °C in 50% formamide, 5× SSC,
0.5% SDS, 0.3 mg/ml salmon sperm DNA, 1× Denhardt's solution.
Radioactive human c-Myc DNA probe (100 ng) (Geneka Biotechnology Inc.,
Montreal, Quebec, Canada) was used at a concentration of 0.5-1 × 106 cpm/ml and was prepared by the random primer labeling
method with [ -32P]dCTP. After hybridization, the
membranes were washed in 0.1-0.5× SSC, 0.1% SDS at 42-68 °C and
exposed to x-ray film.
Isolation of Mitochondria--
697 cells with vector or NTD-MR
were treated with 1 µM TA for 0, 24, and 48 h and
harvested by centrifugation at 600 × g for 10 min at
4 °C. The cell pellets were washed once with ice-cold PBS and
resuspended with 5 volumes of buffer A (20 mM Hepes-KOH (pH
7.5), 10 mM KCl, 1.5 mM MgCl2, 1 mM sodium EDTA, 1 mM sodium EGTA, 1 mM dithiothreitol, and 0.1 mM
phenymethylsulfonyl fluoride) containing 250 mM sucrose.
The cells were homogenized for 15 s, and the homogenates were
centrifuged twice at 750 × g for 10 min at 4 °C.
The supernatants were centrifuged at 10,000 × g for 15 min at 4 °C, and the resulting mitochondrial pellets were
resuspended in buffer A containing 250 mM sucrose and
frozen in multiple samples at 80 °C. The supernatants of the
10,000 × g spin were further centrifuged at
100,000 × g for 1 h or more at 4 °C, and the
resulting cytosolic fractions were concentrated through a Microcon
YM-10 Centrifugal Filter Device (Millipore, Bedford, MA). Mitochondrial and cytosolic fractions were used for Western blot analysis.
 |
RESULTS |
We have demonstrated previously (18, 29) that the NTD of MR is
inhibitory for GR-mediated gene transcriptional regulation. To examine
the ability of this region to modulate GR-induced apoptosis, the NTD of
MR (NTD-MR) composed of amino acids 1-516, or the NTD of GR (NTD-GR),
encompassing amino acids 1-421, was stably expressed in 697 cells.
These cells provide a model system for this study because we have shown
previously (30, 31) that they express GR, and that they are exquisitely
sensitive to GC-induced cell death. More importantly, immunoblot and
RT-PCR analyses of 697 whole cell extracts and of RNA, respectively,
have demonstrated that these cells do not express MR (data not shown).
As shown in Fig. 1, expression of the
NTD-MR/c-Myc or NTD-GR/c-Myc fusion proteins was evaluated by Western
blot analysis using a c-Myc mAb (Fig. 1). The predicted 59-kDa
recombinant NTD-MR protein was detected in 5 of 6 clones examined (Fig.
1A, lanes 1-6), although no c-Myc-tagged NTD-MR
was expressed in the cells transfected with the control vector
(lane 7). Expression of the 51-kDa recombinant NTD-GR
protein was also detected in stably transfected cells (Fig. 1C, lanes 1-6). Following evidence of
expression, the clones with the highest level of NTD-MR (MR-H7 or -A2)
or NTD-GR (GR-D6) were used for further experimentation.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 1.
A and C, detection of
recombinant NTD-MR and NTD-GR in stably transfected 697 cells. Samples
containing whole cell extracts prepared from 1 × 106
cells transfected with vector alone (pCMV), NTD-MR/c-Myc, or
with NTD-GR/c-Myc were subjected to SDS-PAGE followed by immunoblotting
with a c-Myc mAb. Molecular mass markers are indicated (kDa).
B and D, kinetics of 697 cell survival following
GC treatment. At time 0, 697 cells stably transfected with either
vector alone, NTD-GR (clone D6), or NTD-MR (clones H7 and A2) were
cultured in the presence or absence of 1 µM TA, and
survival was analyzed over time by trypan blue exclusion. Data shown
are means and standard deviations for three experiments in which each
was performed in triplicate.
|
|
NTD-MR Inhibits Glucocorticoid-induced Apoptosis in 697 Cells--
To examine the effects of NTD-MR or NTD-GR on the kinetics
of GC-induced cell death, cells were treated with 1 µM TA
for a 48-h time course. Fig. 1D shows that 697 cells with
vector and NTD-GR cells exhibit declining viability within the first
24 h of treatment, with complete cell death occurring by 48 h. Importantly, stable transfection of the NTD-MR in these cells
resulted in a strong inhibition of GC-induced cell death (Fig.
1B). To confirm that overexpression of the MR N terminus
protects 697 cells from GC-induced apoptosis, DNA isolated from cells
at the indicated time points following treatment with 1 µM TA (0, 24, and 48 h) was examined for nuclear
fragmentation using the TUNEL assay. As shown in Fig.
2, 697 cells with vector, treated with TA
for 24 h, exhibited the typical morphologic changes associated
with apoptosis such as shrinkage and nuclear blebbing, compared with untreated cells (Fig. 2, A and B). Moreover, the
nuclei of these cells exhibited fluorescence indicating the presence of
the labeled 3'-OH ends characteristic of apoptotic cells. In contrast,
cells stably expressing NTD-MR, which had been treated with TA for the same time period, retained their viability (Fig. 2, C and
D).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 2.
Stable expression of NTD-MR inhibits
GC-induced apoptosis in 697 cells. 697 cells with vector or
NTD-MR (MR-H7) were incubated in the presence or absence of 1 µM TA. At the 24-h time point, aliquots of cell
suspensions were processed using the TUNEL assay (green) and
counterstained with 4,6-diamidino-2-phenylindole (blue) to
detect changes in nuclear morphology.
|
|
NTD-MR Does Not Affect GR Expression or Nuclear
Translocation--
To explore the mechanism of inhibition of
GC-induced apoptosis by NTD-MR at the receptor level, we first examined
GR protein levels by Western blot and GR subcellular localization by
immunofluorescence. To compare GR protein levels in 697 and MR-H7
cells, whole cell extracts were prepared from cells harvested at 0, 3, 8, 12, 18, 24, 36, and 48 h of treatment with 1 µM
TA. As shown in Fig. 3A, overexpression of NTD-MR did not alter endogenous levels of GR protein,
which remained steady over the 48-h time course and comparable with
those levels detected in 697 cells. Immunocytochemical analysis in Fig.
3B revealed that endogenous GR expression in cells stably transfected with NTD-MR (MR-H7) is cytoplasmic. Following treatment of
cells with 1 µM TA for 1 h, the GR was detected
primarily in the nucleus. These data suggest that the expression of
NTD-MR in 697 cells does not prevent translocation of the GR into the nucleus upon hormone binding.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 3.
Subcellular localization and expression
levels of endogenous GR in MR-H7 cells treated with GC. A,
697 cells with vector or NTD-MR were treated with 1 µM TA
over a 48-h time course, harvested at designated time points, and
subjected to SDS-PAGE followed by immunoblotting with a GR pAb.
Accuracy of protein loading and transfer was confirmed by stripping and
reprobing with a -actin pAb (Santa Cruz Biotechnology).
B, untreated MR-H7 cells (T0) or
cells treated with 1 µM TA for 1 h
(T1) were processed for immunofluorescence using
a GR pAb and confocal microscopy.
|
|
NTD-MR Does Not Affect the Ability of GR to Bind DNA--
To
determine whether the expression of NTD-MR interferes with the ability
of GR to bind DNA, EMSA was performed using a GR/MR-specific response
element as a probe and nuclear extracts from 697 cells with vector or
MR-H7 cells treated for an hour with 1 µM TA. In extracts
of 697 cells, we detected protein binding to the 1 MRE/GRE corresponding to endogenous GR (Fig.
4A, lane 1). This
binding was reduced when a GR antibody was included in the gel shift
reaction (Fig. 4A, lane 2) and was unaffected in
the presence of nonspecific serum (Fig. 4A, lane
3) or c-Myc mAb (Fig. 4A, lane 4). In
extracts of MR-H7 cells, binding of endogenous GR to the 1 MRE/GRE
was similar to that seen for 697 cells (Fig. 4B, lanes
1 and 2). To determine whether the protein-DNA
complexes contained the N-terminal MR, we used two different c-Myc mAbs
and MR pAbs. In all cases, the protein-DNA complexes were either
ablated or shifted to a higher position when these antibodies were used
(Fig. 4B, lanes 3-6) but remained unchanged when
a preimmune serum was included in the reaction (Fig.
4B, lane 7). These results indicate that the N
terminus of MR is present with the GR in the protein-DNA complex,
suggesting the possibility of MR-GR heterodimer formation.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 4.
NTD-MR physically associates with endogenous
GR. EMSA was performed using a GR/MR-specific response element as
a probe and nuclear extracts from 697 cells with vector or NTD-MR
(MR-H7) treated with 1 µM TA for 1 h. A,
GR pAb ( GR) or c-Myc mAb ( myc) was
incubated with nuclear extracts 10 min prior to the addition of probe
(lanes 2 and 4, respectively). Lane 1 contained a buffer control and lane 3 a preimmune
nonspecific serum (NSS). The asterisk denotes
GR-specific binding, and the arrow indicates the
antibody-mediated shifts on DNA-protein complexes. Ab,
antibody. B, MR (lane 4) or hMRsN
(lane 6) pAb was incubated with nuclear extracts 10 min
prior to the addition of probe. Similarly, a c-Myc mAb
( myc) from Invitrogen or from CN Biosciences was
incubated with samples in lanes 3 and 5,
respectively. Lane 1 contained a buffer control, lane
2 GR, and lane 7 a preimmune nonspecific serum
(NSS). C, schematic representation of NTD-MR
derivatives 103, 203, 303, 403, MR-H7, and 603 cloned into the
pCMV/myc/nuc vector. D, 697 cells with vector, NTD-MR, or
stably expressed NTD-MR derivatives 103, 203, 303, 403, and 603 were
treated with 1 µM TA and harvested after 3 h.
Cellular lysates were subjected to immunoprecipitation with c-Myc mAb
and analyzed by Western blot using a GR pAb (top) or a c-Myc
mAb (bottom) as a control for the amount of
immunoprecipitated protein. In lane 3, lysate from cells
transfected with full-length GR served as a positive control.
|
|
Interaction between GR and Amino Acids 203-603 of NTD-MR--
We
have shown previously (18, 29) that when co-expressed, the MR and the
GR are able to form heterodimers. To determine whether the inhibitory
effects of NTD-MR on GR function are the result of a direct interaction
with the GR, we performed immunoprecipitation analysis. 697 cells
stably expressing NTD-MR (MR-H7) or NTD derivatives (1-103, 1-203,
1-303, 1-403, and 1-603) (Fig. 4C) were treated with 1 µM TA for 3 h. Cell lysates were subjected to
immunoprecipitation using a c-Myc mAb. As shown in Fig. 4D
(top), Western blot analysis with a GR pAb demonstrated that
endogenous GR physically associates with the NTD of the MR.
Specifically, this interaction occurred within the N-terminal region
encompassing amino acids 203-603 (lanes 5-9), because no
binding was detected with the deletion derivative 1-103 (lane
4). As a control for the amount of immunoprecipitated protein, the
membrane was stripped and successively reprobed with a c-Myc mAb
(bottom).
Effect of NTD-MR on GR Transcriptional Activity--
To test the
effect of GR/NTD-MR heterodimers on GR transcriptional activity in 697 and MR-H7 cells, we evaluated the effect of TA on GR-mediated
regulation of the endogenous c-myc gene. Suppression of
c-Myc mRNA has been reported previously (31) when GR-sensitive
cells were treated with GC. To examine the expression of c-Myc at the
mRNA level, 697 cells with vector or NTD-MR were cultured in the
presence of 1 µM TA for 48 h, and RNA was prepared from cells harvested at time 0, 4, 16, 24, and 48 h. As determined by semi-quantitative RT-PCR, treatment of 697 cells with GC caused a
7-fold repression of c-Myc transcription by 24 h as compared with
untreated cells (time 0) (Fig.
5A). This repression was
blocked by NTD-MR in MR-H7 cells as shown in Fig. 5A. GAPDH
levels were unaffected by TA treatment in both cell lines. These data
were confirmed by Northern blot analysis using a c-Myc-specific
cDNA probe in Fig. 5B, which shows that expression of
c-Myc mRNA was dramatically reduced in 697 cells treated with TA
after 4 h. Within the period of the experiment, the level of the
c-Myc mRNA reached its lowest point at 24 h after TA
treatment. However, in the MR-H7 cells, c-Myc mRNA levels remained
constant throughout the time course.

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of TA on the expression of c-Myc
mRNA in 697 and MR-H7 cells. A, gel electrophoresis of
semi-quantitative RT-PCR using 1 µg of total cellular RNA from 697 cells with vector or NTD-MR (MR-H7) harvested at indicated
time points throughout a 48-h incubation with 1 µM TA.
GAPDH was included as an internal control. Fold induction
(FI) of c-Myc mRNA expression is indicated.
B, total cellular RNA was isolated from 697 cells with
vector (lanes 1-5) or NTD-MR (MR-H7)
(lanes 6-10) at 0-48 h after TA (1 µM)
treatment. Equal amounts of RNA (15 µg/lane) were fractionated on an
agarose-formaldehyde gel (top) and transferred by blotting
onto Hybond-N nylon membranes as described under "Experimental
Procedures." The c-Myc mRNA was identified by hybridization using
a 1-kb 32P-labeled human c-Myc probe (bottom).
The locations of the 28 S and 18 S rRNAs are indicated. The periods
of TA treatment (h) are indicated at the top of
each lane.
|
|
NTD-MR Inhibits Proteolytic Processing of Caspases and PARP--
A
common end point to apoptosis is a network of caspases whose activation
is required for the irreversible commitment to cell death. To determine
whether NTD-MR expression inhibits caspase activation in 697 cells,
enzymatic cleavage of endogenous caspases during GC-induced apoptosis
was assessed. 697 cells stably expressing NTD-MR (MR-H7) or vector
alone were cultured in the presence or absence of 1 µM TA
during a 48-h time course, and whole cell lysates were examined by
Western blot analysis. As shown in Fig.
6A, proteolytic processing of
the proform of the apical caspases-8 (55 kDa) and -9 (46 kDa) and the
downstream effector caspase-3 (32 kDa) was observed in 697 cells
treated with TA. In contrast, in MR-H7 cells treated with TA, the
inactive proenzyme forms of caspases-8, -9, and -3 remained intact,
revealing that GC-induced caspase cleavage was abolished. Further
evidence of this inhibition was seen when a downstream target of
activated caspase-3, PARP, was examined for enzymatic degradation.
Immunoblot analysis in Fig. 6B shows that following
treatment of 697 cells with TA, the "death substrate" PARP (116 kDa) was proteolyzed with generation of its signature 85-kDa cleavage
product, although in MR-H7 cells, PARP cleavage was inhibited.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 6.
Stable expression of NTD-MR inhibits caspase
activation and PARP cleavage during GC-induced apoptosis. Western
blot analysis of caspase-8, caspase-9, caspase-3, and PARP status after
treatment with TA. A, 697 cells with vector or NTD-MR
(MR-H7) were treated with 1 µM TA for a 48-h
time course. Samples containing whole cell extracts from 1 × 106 cells were subjected to SDS-PAGE followed by
immunoblotting with a mAb to caspase-8 and pAbs to caspase-9 and active
caspase-3. B, for PARP analysis, samples (50 µg) were
electrophoresed on an 8% SDS-polyacrylamide gel, transferred to
nitrocellulose membrane, and probed with anti-PARP mAb. Molecular mass
markers are indicated (kDa).
|
|
Effect of NTD-MR on Bcl-2 Family Members--
It has been shown
that GC-induced apoptosis is regulated by members of the Bcl-2 family
upstream of caspase activation (32-34). To address potential
mechanisms involved in N-terminal MR inhibition of GC-induced
apoptosis, we evaluated the expression levels of the anti-apoptotic
proteins, Bcl-2 and Bfl-1. As determined by semi-quantitative RT-PCR,
treatment of 697 cells with 1 µM TA caused an 18-fold
repression of Bcl-2 transcription by 16 h; however, in MR-H7
cells, Bcl-2 mRNA levels increased nearly 2-fold over the 48-h time
course (Fig. 7A). We also
observed a 6-fold down-regulation of Bfl-1 mRNA in 697 cells within
4 h of treatment, whereas Bfl-1 mRNA expression in MR-H7 cells
was up-regulated 8-fold (Fig. 7A). These results were
corroborated by Western blot analyses of cytosolic and mitochondrial
extracts. Following GC treatment of 697 cells, mitochondrial levels of
Bcl-2 were decreased, although cytosolic levels increased slightly
(Fig. 7B). In contrast, mitochondrial Bcl-2 levels were
dramatically increased in MR-H7 cells (Fig. 7B).
Furthermore, mitochondrial and cytosolic Bfl-1 expression levels were
non-detectable in 697 cells following GC treatment, whereas in MR-H7
cells, the expression levels of Bfl-1 in the mitochondrial fraction
increased slightly at 24 h and in the cytosolic fraction were
increased at 48 h (Fig. 7B).

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of GC on Bcl-2 and Bfl-1 mRNA
expression and protein levels in 697 and MR-H7 cells. A, gel
electrophoresis of semi-quantitative RT-PCR using 1 µg of total
cellular RNA from 697 cells with vector or (NTD-MR) MR-H7 harvested at
indicated time points throughout a 48-h incubation with 1 µM TA. RT-PCR was performed as described under
"Experimental Procedures" using the following primer pairs: Bcl-2
forward, 5'-ATGGCGCACGCTGGGAGAACGGGGTACGAC-3', and Bcl-2
reverse, 5'-TCACTTGTGGCTCAGATAGGCACCCAGGGT-3'; Bfl-1 forward,
5'-ATGACAGACTGTGAATTTGGATATATTTAC-3', and Bfl-1 reverse
5'-TCAACAGTATTGCTTCAGGAGAGATAGCAT-3'. GAPDH was included as an
internal control. Fold induction (FI) of Bcl-2 and Bfl-1
mRNA expression is indicated. B, mitochondrial and
cytosolic extracts from 697 cells with vector or NTD-MR
(MR-H7) treated with 1 µM TA for a 48-h time
course were subjected to SDS-PAGE followed by immunoblotting with a mAb
to Bcl-2 (BD Biosciences) and a pAb to Bfl-1 (Santa Cruz
Biotechnology). To ensure that the same content of mitochondrial and
cytosolic protein was loaded in each case, the membrane was stripped
and successively reprobed with a VDAC pAb (Santa Cruz Biotechnology) as
a marker for the mitochondrial fraction and a -actin pAb as a marker
for the cytosolic fraction.
|
|
A recent study (35) has demonstrated that Bfl-1 can prevent the
formation of a pro-apoptotic complex by sequestering BH3 domain-only
proteins like Bid and blocking its collaboration with Bax or Bak in the
plane of the mitochondrial membrane. Thus, we examined the localization
and protein levels of the pro-apoptotic proteins Bid and Bax in 697 and
MR-H7 cells treated with 1 µM TA. Western blot analysis
in Fig. 8A shows that in 697 cells, both cytosolic and mitochondrial levels of Bid were dramatically higher than in MR-H7 cells. Moreover, in MR-H7 cells, Bid was located
primarily within the mitochondria, whereas in 697 cells it was detected
in the cytosol as well. Bax protein levels did not seem to be
significantly different between the two cell lines; however, Bax was
only faintly detectable in the cytosol of MR-H7 cells at 48 h
(Fig. 8A).

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 8.
A, localization of Bid, Bax, Cyt c, and
Smac in GC-treated 697 and MR-H7 cells. Mitochondrial and cytosolic
extracts from 697 cells with vector or NTD-MR (MR-H7) treated with 1 µM TA for a 48-h time course were subjected to SDS-PAGE
followed by immunoblotting with a pAb to Bid
(BIOSOURCE), a pAb to Bax (Santa Cruz
Biotechnology), a mAb to Cyt c (BD Biosciences), and a pAb to
Smac/DIABLO (Upstate Biotechnology, Inc.). To ensure that the same
content of mitochondrial and cytosolic protein was loaded in each case,
the membrane was stripped and successively reprobed with a VDAC pAb as
a marker for the mitochondrial fraction and a -actin pAb as a marker
for the cytosolic fraction. B, NTD-MR inhibits degradation
of XIAP after treatment with TA. Cytosolic extracts from 697 cells with
vector or NTD-MR (MR-H7) treated with 1 µM TA for a 48-h
time course were subjected to SDS-PAGE followed by immunoblotting with
a mAb to XIAP (Stressgen). Accuracy of protein loading and transfer was
confirmed by stripping and reprobing with a -actin pAb.
|
|
NTD-MR Inhibits Cytochrome c and Smac Release from the
Mitochondria--
Bcl-2 has been shown to inhibit cytochrome
c (Cyt c) release from mitochondria in pre-apoptotic cells
(36). Because we observed reduced expression of Bcl-2 in GC stimulated
697 cells and increased expression in MR-H7 cells, we sought to examine
whether Cyt c was released from the mitochondria. As shown in Fig.
8A, GC induced a time-dependent release of Cyt c
from the mitochondria with a concomitant increase of Cyt c into the
cytosolic fraction of 697 cells. In contrast, Cyt c was retained in the
mitochondria of MR-H7 cells (Fig. 8A). Because Smac/DIABLO
is known to promote caspase activation in the Cyt-c/Apaf-1/caspase-9
pathway, we examined whether inhibition of Smac release from the
mitochondria plays a role in NTD-MR-mediated inhibition of GC-induced
apoptosis. As demonstrated in Fig. 8A, the expression level
of Smac in the mitochondrial fraction of 697 cells was dramatically
reduced within 48 h following treatment with 1 µM
TA. This loss of Smac from the mitochondria was accompanied by its
presence in the cytosol within 24 h, an effect that was inhibited
in the presence of NTD-MR (Fig. 8A). These results
demonstrate that GC-induced apoptosis in 697 cells is accompanied by
the release of Cyt c and Smac from the mitochondria into the cytosol
and that the expression of NTD-MR inhibits this process.
Smac/DIABLO, when released from mitochondria into the cytosol,
functions by eliminating the inhibitory effects of inhibitor of
apoptosis proteins (IAPs), particularly XIAP, on caspases (37-39). We
examined the cytosolic fractions from GC-treated 697 and MR-H7 cells
for the presence of XIAP. As shown in Fig. 8B, XIAP levels were relatively low in 697 cells and completely diminished by 48 h. However, in MR-H7 cells, levels of XIAP were much higher and
remained constant throughout the 48-h time course (Fig. 8B). These data are important because they support a model in MR-H7 cells
that by inhibiting the release of Smac from the mitochondria, XIAP is
able to maintain its association with caspases and inhibit their
activity as well as cell death.
 |
DISCUSSION |
GC-induced lymphocytic cell death is one of the earliest
recognized forms of apoptosis (8), yet progress in understanding this
process has lagged behind significant advances in understanding other
forms of apoptosis, such as that induced by death receptors (40). In
this report, we examined the ability of the NTD of MR to modulate
GR-induced apoptosis in the GC-sensitive cell line, 697, based on our
previous findings that this region is inhibitory for GR-mediated gene
transcriptional regulation (18, 29). Our data show that when treated
with the GC analog, TA, parental 697 cells undergo apoptosis. However,
in 697 cells stably expressing the NTD-MR, GC-induced apoptosis
was dramatically inhibited, indicating that the N-terminal region of MR
induces a dominant negative effect and potently inhibits GR function.
Inhibition of GC-induced apoptosis in 697 cells by NTD-MR may reflect
interactions occurring at the receptor level. In its inactivated form,
the GR exists in the cytoplasm of cells complexed with heat-shock
proteins, immunophilins, and other inhibitory proteins (41). Upon
binding ligand, the GR sheds these proteins and translocates to the
nucleus, where it can regulate the transcription of GC-responsive genes
by binding to specific glucocorticoid-response elements (GREs) within
DNA, either enhancing or repressing gene transcription (42). We show
that overexpression of NTD-MR does not prevent translocation of the GR
into the nucleus upon hormone binding nor does it alter endogenous GR
protein levels. However, EMSA and immunoprecipitation analyses
demonstrate that there is a direct interaction between the GR and amino
acids 203-603 of the NTD-MR. An evaluation of GR transcriptional
activity in both 697 and MR-H7 cells further revealed that NTD-MR
expression interfered with the GR-mediated suppression of endogenous
c-Myc. These results suggest that the observed inhibitory activity of
NTD-MR on GR-mediated transcription and ensuing apoptosis in 697 cells
is likely mediated through heterodimerization of the NTD-MR with GR.
Importantly, these data are in agreement with several studies (18-20,
43) substantiating the potential for transcriptional regulation via heteromeric complexes of the GR and MR.
In mammals, the initiation of apoptosis is controlled by the following
two major signaling pathways: the receptor-mediated "extrinsic"
pathway and the mitochondrial-mediated "intrinsic" pathway.
Caspase-8 is the key initiator of the extrinsic pathway where it is
activated in response to death receptor engagement by ligands belonging
to the tumor necrosis factor superfamily (44, 45). The intrinsic
pathway involves mitochondrial disruption by pro-apoptotic Bcl-2 family
members and consequent release of factors such as cytochrome
c that promote caspase-9 activation (46-49). Both pathways
culminate in the activation of downstream effector caspases-3, -6, and
-7 and can cooperate to enhance apoptosis through caspase-8-mediated
cleavage of Bid (50-52). Here we provide evidence that treatment of
697 cells with GC mediates the efficient proteolytic processing of
caspases-8, -9, and -3 as well as cleavage of the death substrate,
PARP. Remarkably, this processing is completely abolished in 697 cells
expressing NTD-MR, suggesting that the survival function of NTD-MR is
upstream of caspase activation. Our observation that GC-induced
apoptosis in 697 cells is accompanied by the cleavage of caspases-9 and
-3 as well as the release of Cyt c from the mitochondria provides
strong evidence that apoptosis in pre-B lymphocytes proceeds mainly
through the intrinsic cell death pathway.
Members of the Bcl-2 family, including death repressor (e.g.
Bcl-2, Bcl-xL, and Bfl-1) and death inducer
(e.g. Bax, Bcl-xS, and Bak) proteins, are major
regulators of mitochondrial apoptotic events and act in part by
controlling Cyt c release from the mitochondria (53). For example,
expression of Bcl-2 and Bcl-xL prevents the redistribution
of Cyt c in response to multiple death-inducing stimuli (54-56),
whereas Bid, Bax, and Bak promote Cyt c release (36, 57, 58). Bcl-2
family members also form homo- or heterodimers with one another and,
depending on the ratio of inhibitor to activator, can either inhibit or
activate cell death (59, 60). In the present study, we observed that
stimulation of 697 cells with GC triggered the loss of Bcl-2 and Bfl-1
expression and the release of cytochrome c and Smac from the
mitochondria. Moreover, levels of the pro-apoptotic proteins Bax and
Bid remained elevated, supporting destructive alterations in the
mitochondria. In sharp contrast, 697 cells stably expressing NTD-MR
exhibited increased expression levels of Bcl-2 and Bfl-1 and inhibition
of Cyt c and Smac release from the mitochondria. The protein levels of
Bid and Bax in these cells were either significantly reduced or not
sustained over the 48-h treatment period with TA, supporting the
inhibition of mitochondrial disruption in these cells. Furthermore, the
elevated levels of XIAP observed in MR-H7 cells suggest that XIAP would be allowed to maintain its association with caspases and prevent apoptosis.
The observed up-regulation of the anti-apoptotic proteins, Bcl-2 and
Bfl-1, in MR-H7 cells sheds light not only on the mechanism by which
NTD-MR inhibits the pro-apoptotic action of GCs but also on the process
by which GCs induce apoptosis in pre-B lymphocytes. Recent findings
indicate that Bcl-2 family members function upstream of caspase
activation to inhibit commitment to cell death. Bcl-2 is thought to act
on the outer mitochondrial membrane to prevent mitochondrial
permeability transition pore opening and the subsequent release of
apoptogenic proteins from the mitochondria (53, 61). Bcl-2 can
also inhibit the action of Bax/Bak by forming inactivating heterodimers
(57). More recently, it has been shown that overexpression of Bcl-2 in
dexamethasone-treated thymocytes inhibits proteasome activation (62).
Involvement of the proteasome in the induction of apoptosis is a
distinguishing characteristic of the corticosteroid-induced death
pathway versus the Fas-mediated cell death pathway where the
proteasome appears dispensable (62). Degradation of the cell cycle
proteins, Cdk2 and p27Kip1 (33, 63), the pro-survival transcription
factors, c-Fos and NF- B (34, 64), and the IAPs, c-IAP1 and XIAP
(60), by the proteasome have been described. Hence, higher levels of
Bcl-2 in MR-H7 cells may act not only to preserve mitochondrial
function but may also function by regulating proteasome-mediated
degradation of cell cycle and pro-survival proteins.
Bfl-1 is an anti-apoptotic Bcl-2 family member whose preferential
expression in hematopoietic cells and endothelium is controlled by
inflammatory stimuli. Cellular expression of Bfl-1 has been shown to
confer protection against CD95- and Trail receptor-induced Cyt c
release as well as p53- and etoposide-induced apoptosis (65-67).
However, a protective function of Bfl-1 in GC-induced apoptosis has not
been documented. We observed localization of Bfl-1 and Bid primarily to
the mitochondria in MR-H7 cells but not in 697 cells undergoing
apoptosis. Bfl-1 has been shown to prevent the formation of a
pro-apoptotic complex by sequestering BH3 domain-only proteins at the
mitochondria. Thus, up-regulation of Bfl-1 in MR-H7 cells may serve to
bind and sequester tBid at the mitochondria and prevent its association
with Bax, thereby inhibiting mitochondrial disruption and Cyt c release.
A possible mechanism for the inhibitory effect of NTD-MR on GC-induced
apoptosis may involve the disruption of an interaction between GR and a
specific cellular factor or competition between the GR and NTD-MR for
limited amounts of mutual coactivators. A coactivator that clearly
distinguishes between the GR and MR has not been identified; however,
it is likely that coactivators interacting differentially with the AF-1
transactivation domain of these receptors may play an important role in
conferring specific glucocorticoid/mineralocorticoid-mediated
regulation. A recent study by Sadar and co-workers (68) has
demonstrated that interleukin-6 mediates activation of the androgen
receptor NTD by a mechanism dependent upon mitogen-activated protein
kinase and STAT3 signal transduction pathways in LNCaP prostate cancer
cells. Furthermore, STAT3 was shown to interact specifically with
fragments of the androgen receptor NTD containing all or part of the
AF-1 site.
In summary, we have demonstrated that in GC-induced apoptosis of 697 cells, the NTD of MR inhibited apoptosis prior to commitment to cell
death by interfering with GR-mediated changes in gene transcription.
Specifically, we show that GR-mediated repression of c-Myc and of the
anti-apoptotic proteins Bcl-2 and Bfl-1 is abrogated in cells
expressing NTD-MR. The up-regulation of these anti-apoptotic proteins
in MR-H7 cells as well as the diminished levels of Bax and Bid provide
a potential mechanism for the observed inhibition of Cyt c and Smac
release from the mitochondria and resultant resistance to GC-induced
apoptosis. Thus, in normal physiology, in cells where MR and GR are
coexpressed, the MR may function to counteract the role of activated GR
by increasing the ratio of anti-apoptotic molecules relative to
pro-apoptotic molecules. Indeed, such a scenario has been observed in
the rat hippocampus where the opposing actions of MR and GR on neuronal survival were shown to result from their ability to differentially influence the expression of members of the bcl-2 gene family
(69). Further studies are underway to identify GR-induced pro-apoptotic genes that are repressed by NTD-MR and pro-survival genes that are
up-regulated by NTD-MR. The elucidation of GR-regulated apoptotic genes
may offer a molecular basis for the treatment of inflammatory diseases
and cancer.
 |
ACKNOWLEDGEMENTS |
We are grateful to R. M. Evans for
providing the expression plasmids for the human MR and the human GR. We
also thank Dr. Jim Zangrilli and Dr. Annette Hastie for critical review
of the manuscript and members of the Litwack laboratory for
helpful discussions.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grant AI/HL 40976 (to G. L.) and American Lung
Association Grant RG-034N (to N. R.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Supported by National Institutes of Health Training Grant 5T32 DK07705.
§
Present address: NIAMS, National Institutes of Health, Rm. 3W17, 13 South Dr., MSC5755, Bethesda, MD 20892.
¶
To whom correspondence should be addressed: Thomas Jefferson
University, 233 S. 10th St., BLSB 350, Philadelphia, PA 19107. Tel.:
215-503-4634; Fax: 215-503-5393; E-mail:
Gerry.Litwack@mail.tju.edu.
Published, JBC Papers in Press, August 22, 2002, DOI 10.1074/jbc.M205085200
 |
ABBREVIATIONS |
The abbreviations used are:
GR, glucocorticoid
receptor;
Cyt c, cytochrome c;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
GC(s), glucocorticoid(s);
GRE, glucocorticoid-response element;
IAP, inhibitor of apoptosis
protein;
mAb, monoclonal antibody;
MR, mineralocorticoid receptor;
NGS, normal goat serum;
NTD, N-terminal domain;
NTD-MR, N-terminal domain of
MR;
pAb, polyclonal antibody;
PARP, poly(ADP-ribose) polymerase;
PBS, phosphate buffered saline;
TA, triamcinolone acetonide;
wt, wild type;
EMSA, electrophoretic mobility shift analysis;
TUNEL, terminal dUTP
nick-end labeling;
RT, reverse transcriptase.
 |
REFERENCES |
| 1.
|
Arriza, J. L.,
Weinberger, C.,
Cerelli, G.,
Glaser, T. M.,
Handelin, B. L.,
Housman, D. E.,
and Evans, R. M.
(1987)
Science
237,
268-275[Abstract/Free Full Text]
|
| 2.
|
Perlmann, T.,
and Evans, R. M.
(1997)
Cell
90,
391-397[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Arriza, J. L.,
Simerly, R. B.,
Swanson, L. W.,
and Evans, R. M.
(1988)
Neuron
1,
887-900[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Alnemri, E. S.,
Maksymowych, A. B.,
Robertson, N. M.,
and Litwack, G.
(1991)
J. Biol. Chem.
266,
18072-18081[Abstract/Free Full Text]
|
| 5.
|
Liu, W.,
Wang, J.,
Sauter, N. K.,
and Pearce, D.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
12480-12484[Abstract/Free Full Text]
|
| 6.
|
Rupprecht, R.,
Arriza, J. L.,
Spengler, D.,
Reul, J. M.,
Evans, R. M.,
Holsboer, F.,
and Damm, K.
(1993)
Mol. Endocrinol.
7,
597-603[Abstract/Free Full Text]
|
| 7.
|
Pearce, D.,
and Yamamoto, K. R.
(1993)
Science
259,
1161-1165[Abstract/Free Full Text]
|
| 8.
|
Wyllie, A. H.
(1980)
Nature
284,
555-556[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Thompson, E. B.
(1994)
Mol. Endocrinol.
8,
665-673[Free Full Text]
|
| 10.
|
Evans-Storms, R. B.,
and Cidlowski, J. A.
(1995)
J. Steroid Biochem. Mol. Biol.
53,
1-8[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Thompson, E. B.,
Thulasi, R.,
Saeed, M. F.,
and Johnson, B. H.
(1995)
Ann. N. Y. Acad. Sci.
761,
261-275[Medline]
[Order article via Infotrieve]
|
| 12.
|
Caron-Leslie, L. A.,
and Cidlowski, J. A.
(1991)
Mol. Endocrinol.
5,
1169-1179[Abstract/Free Full Text]
|
| 13.
|
Tronche, F.,
Kellendonk, C.,
Reichardt, H. M.,
and Schutz, G.
(1998)
Curr. Opin. Genet. & Dev.
8,
532-538[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Harbour, D. V.,
Chambon, P.,
and Thompson, E. B.
(1990)
J. Steroid Biochem.
35,
1-9[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Nazareth, L. V.,
Harbour, D. V.,
and Thompson, E. B.
(1991)
J. Biol. Chem.
266,
12976-12980[Abstract/Free Full Text]
|
| 16.
|
Dieken, E. S.,
and Meisfeld, R. L.
(1992)
Mol. Cell. Biol.
12,
589-597[Abstract/Free Full Text]
|
| 17.
|
Hollenberg, S. M.,
and Evans, R. M.
(1988)
Cell
55,
899-906[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Derfoul, A.,
Robertson, N. M.,
Hall, D. J.,
and Litwack, G.
(2000)
Endocrine
13,
287-295[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Trapp, T.,
Rupprecht, R.,
Castren, M.,
Reul, J. M.,
and Holsboer, F.
(1994)
Neuron
13,
1457-1462[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Ou, X. M.,
Storring, J. M.,
Kushwaha, N.,
and Albert, P. R.
(2001)
J. Biol. Chem.
276,
14299-14307[Abstract/Free Full Text]
|
| 21.
|
Trapp, T.,
and Holsboer, F.
(1996)
Trends Pharmacol. Sci.
17,
145-149[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Zennaro, M. C.,
Farman, N.,
Bonvalet, J. P.,
and Lombes, M.
(1997)
J. Clin. Endocrinol. Metab.
82,
1345-1352[Abstract/Free Full Text]
|
| 23.
|
Wickert, L.,
Watzka, M.,
Bolkenius, U.,
Bidlingmaier, F.,
and Ludwig, M.
(1998)
Eur. J. Endocrinol.
138,
702-704[Abstract]
|
| 24.
|
van Steensel, B.,
van Binnendijk, E. P.,
Hornsby, C. D.,
van der Voort, H. T.,
Krozowski, Z. S.,
de Kloet, E. R.,
and van Driel, R.
(1996)
J. Cell Sci.
109,
787-792[Abstract]
|
| 25.
|
Hassan, A. H.,
von Rosenstiel, P.,
Patchev, V. K.,
Holsboer, F.,
and Almeida, O. F.
(1996)
Exp. Neurol.
140,
43-52[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Tsujimoto, Y.,
Cossman, J.,
Jaffe, E.,
and Croce, C. M.
(1985)
Science
228,
1440-1443[Abstract/Free Full Text]
|
| 27.
|
Williams, D. L.,
Look, A. T.,
Melvin, S. L.,
Roberson, P. K.,
Dahl, G.,
Flake, T.,
and Stass, S.
(1984)
Cell
36,
101-109[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Robertson, N. M.,
Schulman, G.,
Karnik, S.,
Alnemri, E.,
and Litwack, G.
(1993)
Mol. Endocrinol.
7,
1226-1239[Abstract/Free Full Text]
|
| 29.
|
Derfoul, A.,
Robertson, N. M.,
Lingrel, J. B.,
Hall, D. J.,
and Litwack, G.
(1998)
J. Biol. Chem.
273,
20702-20711[Abstract/Free Full Text]
|
| 30.
|
Robertson, N. M.,
Zangrilli, J.,
Fernandes-Alnemri, T.,
Friesen, P. D.,
Litwack, G.,
and Alnemri, E. S.
(1997)
Cancer Res.
57,
43-47[Abstract/Free Full Text]
|
| 31.
|
Alnemri, E. S.,
Fernandes, T. F.,
Haldar, S.,
Croce, C. M.,
and Litwack, G.
(1992)
Cancer Res.
52,
491-495[Abstract/Free Full Text]
|
| 32.
|
Brunet, C. L.,
Gunby, R. H.,
Benson, R. S.,
Hickman, J. A.,
Watson, A. J.,
and Brady, G.
(1998)
Cell Death Differ.
5,
107-115[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Hakem, A.,
Sasaki, T.,
Kozieradzki, I.,
and Penninger, J. M.
(1999)
J. Exp. Med.
189,
957-968[Abstract/Free Full Text]
|
| 34.
|
Feinman, R.,
Koury, J.,
Thames, M.,
Barlogie, B.,
Epstein, J.,
and Siegel, D. S.
(1999)
Blood
93,
3044-3052[Abstract/Free Full Text]
|
| 35.
|
Werner, A. B.,
de Vries, E.,
Tait, S. W.,
Bontjer, I.,
and Borst, J.
(2002)
J. Biol. Chem.
277,
22781-22788[Abstract/Free Full Text]
|
| 36.
|
Finucane, D. M.,
Bossy-Wetzel, E.,
Waterhouse, N. J.,
Cotter, T. G.,
and Green, D. R.
(1999)
J. Biol. Chem.
274,
2225-2233[Abstract/Free Full Text]
|
| 37.
|
Srinivasula, S. M.,
Datta, P.,
Fan, X. J.,
Fernandes-Alnemri, T.,
Huang, Z.,
and Alnemri, E. S.
(2000)
J. Biol. Chem.
275,
36152-36157[Abstract/Free Full Text]
|
| 38.
|
Du, C.,
Fang, M., Li, Y., Li, L.,
and Wang, X.
(2000)
Cell
102,
33-42[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Verhagen, A. M.,
Ekert, P. G.,
Pakusch, M.,
Silke, J.,
Connolly, L. M.,
Reid, G. E.,
Moritz, R. L.,
Simpson, R. J.,
and Vaux, D. L.
(2000)
Cell
102,
43-53[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Distelhorst, C. W.
(2002)
Cell Death Differ.
9,
6-19[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Pratt, W. B.,
and Toft, D. O.
(1997)
Endocr. Rev.
18,
306-360[Abstract/Free Full Text]
|
| 42.
|
Truss, M.,
and Beato, M.
(1993)
Endocr. Rev.
14,
459-479[Abstract/Free Full Text]
|
| 43.
|
Liu, W.,
Hillmann, A. G.,
and Harmon, J. M.
(1995)
Mol. Cell. Biol.
15,
1005-1013[Abstract]
|
| 44.
|
Ashkenazi, A.,
and Dixit, V. M.
(1998)
Science
281,
1305-1308[Abstract/Free Full Text]
|
| 45.
|
Nunez, G.,
Benedict, M. A., Hu, Y.,
and Inohara, N.
(1998)
Oncogene
17,
3237-3245[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Hu, Y.,
Ding, L.,
Spencer, D. M.,
and Nunez, G.
(1998)
J. Biol. Chem.
273,
33489-33494[Abstract/Free Full Text]
|
| 47.
|
Saleh, A.,
Srinivasula, S. M.,
Acharya, S.,
Fishel, R.,
and Alnemri, E. S.
(1999)
J. Biol. Chem.
274,
17941-17945[Abstract/Free Full Text]
|
| 48.
|
Zou, H., Li, Y.,
Liu, X.,
and Wang, X.
(1999)
J. Biol. Chem.
274,
11549-11556[Abstract/Free Full Text]
|
| 49.
|
Green, D. R.
(2000)
Cell
102,
1-4[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Li, H.,
Zhu, H., Xu, C. J.,
and Yuan, J.
(1998)
Cell
94,
491-501[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Luo, X.,
Budihardjo, I.,
Zou, H.,
Slaughter, C.,
and Wang, X.
(1998)
Cell
94,
481-490[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Roy, S.,
and Nicholson, D. W.
(2000)
J. Exp. Med.
192,
F21-F25[Free Full Text]
|
| 53.
|
Kroemer, G.,
and Reed, J. C.
(2000)
Nat. Med.
6,
513-519[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Kluck, R. M.,
Bossy-Wetzel, E.,
Green, D. R.,
and Newmeyer, D. D.
(1997)
Science
275,
1132-1136[Abstract/Free Full Text]
|
| 55.
|
Vander Heiden, M. G.,
Chandel, N. S.,
Williamson, E. K.,
Schumacker, P. T.,
and Thompson, C. B.
(1997)
Cell
91,
627-637[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Gross, A.,
Yin, X. M.,
Wang, K.,
Wei, M. C.,
Jockel, J.,
Milliman, C.,
Erdjument-Bromage, H.,
Tempst, P.,
and Korsmeyer, S. J.
(1999)
J. Biol. Chem.
274,
1156-1163[Abstract/Free Full Text]
|
| 57.
|
Oltivai, Z. N.,
Milliman, C. L.,
and Korsmeyer, S. J.
(1993)
Cell
74,
609-619[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Yin, X. M.
(2000)
J. Mol. Med.
78,
203-211[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Oltvai, Z. N.,
and Korsmeyer, S. J.
(1994)
Cell
79,
189-192[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Yang, Y.,
Fang, S.,
Jensen, J. P.,
Weissman, A. M.,
and Ashwell, J. D.
(2000)
Science
288,
874-877[Abstract/Free Full Text]
|
| 61.
|
Gross, A.,
McDonnell, J. M.,
and Korsmeyer, S. J.
(1999)
Genes Dev.
13,
1899-1911[Free Full Text]
|
| 62.
|
Dallaporta, B.,
Pablo, M.,
Maisse, C.,
Daugas, E.,
Loeffler, M.,
Zamzami, N.,
and Kroemer, G.
(2000)
Cell Death Differ.
7,
368-373[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Gil-Gomez, G.,
Berns, A.,
and Brady, H. J.
(1998)
EMBO J.
17,
7209-7218[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
He, H., Qi, X. M.,
Grossmann, J.,
and Distelhorst, C. W.
(1998)
J. Biol. Chem.
273,
25015-25019[Abstract/Free Full Text]
|
| 65.
|
Wang, C. Y.,
Guttridge, D. C.,
Mayo, M. W.,
and Baldwin, A. S., Jr.
(1999)
Mol. Cell. Biol.
19,
5923-5929[Abstract/Free Full Text]
|
| 66.
|
D'Sa-Eipper, C.,
Subramanian, T.,
and Chinnadurai, G.
(1996)
Cancer Res.
56,
3879-3882[Abstract/Free Full Text]
|
| 67.
|
D'Sa-Eipper, C.,
and Chinnadurai, G.
(1998)
Oncogene
16,
3105-3114[CrossRef][Medline]
[Order article via Infotrieve]
|
| 68.
|
Ueda, T.,
Bruchovsky, N.,
and Sadar, M. D.
(2002)
J. Biol. Chem.
277,
7076-7085[Abstract/Free Full Text]
|
| 69.
|
Almeida, O. F.,
Conde, G. L.,
Crochemore, C.,
Demeneix, B. A.,
Fischer, D.,
Hassan, A. H.,
Meyer, M.,
Holsboer, F.,
and Michaelidis, T. M.
(2000)
FASEB J.
14,
779-790[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Sola, J. D. Amaral, P. M. Borralho, R. M. Ramalho, R. E. Castro, M. M. Aranha, C. J. Steer, and C. M. P. Rodrigues
Functional Modulation of Nuclear Steroid Receptors by Tauroursodeoxycholic Acid Reduces Amyloid {beta}-Peptide-Induced Apoptosis
Mol. Endocrinol.,
October 1, 2006;
20(10):
2292 - 2303.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Freeman, M. Hewison, S. V. Hughes, K. N. Evans, D. Hardie, T. K. Means, and R. Chakraverty
Expression of 11{beta}-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells
Blood,
September 15, 2005;
106(6):
2042 - 2049.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Pascual-Le Tallec and M. Lombes
The Mineralocorticoid Receptor: A Journey Exploring Its Diversity and Specificity of Action
Mol. Endocrinol.,
September 1, 2005;
19(9):
2211 - 2221.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Pascual-Le Tallec, F. Simone, S. Viengchareun, G. Meduri, M. J. Thirman, and M. Lombes
The Elongation Factor ELL (Eleven-Nineteen Lysine-Rich Leukemia) Is a Selective Coregulator for Steroid Receptor Functions
Mol. Endocrinol.,
May 1, 2005;
19(5):
1158 - 1169.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. F. Walther, E. Atlas, A. Carrigan, Y. Rouleau, A. Edgecombe, L. Visentin, C. Lamprecht, G. C. Addicks, R. J. G. Hache, and Y. A. Lefebvre
A Serine/Threonine-rich Motif Is One of Three Nuclear Localization Signals That Determine Unidirectional Transport of the Mineralocorticoid Receptor to the Nucleus
J. Biol. Chem.,
April 29, 2005;
280(17):
17549 - 17561.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. T. Abrams, N. M. Robertson, K. Yoon, and E. Wickstrom
Inhibition of Glucocorticoid-induced Apoptosis by Targeting the Major Splice Variants of BIM mRNA with Small Interfering RNA and Short Hairpin RNA
J. Biol. Chem.,
December 31, 2004;
279(53):
55809 - 55817.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|